CIPN is a debilitating condition in which chemotherapy drugs damage the peripheral nerves, most often those serving the hands and feet. Patients typically experience numbness, tingling, burning pain, and loss of fine motor control. In severe cases, the symptoms persist for months or years after treatment ends, and there is currently no approved drug that reliably prevents or reverses the damage. Because paclitaxel, a mainstay taxane chemotherapy for breast cancer, is among the most neuropathy-inducing agents in clinical use, the search for a practical preventive measure has become a major priority in supportive oncology care.

The logic behind cryotherapy is elegantly straightforward. When a patient’s hands and feet are cooled during the infusion of chemotherapy, blood vessels in those extremities constrict, a process known as vasoconstriction. This reduces local blood flow, which in turn limits the amount of drug delivered to the small nerve fibers in the fingers and toes. Cooling also slows metabolic activity in nerve tissue and may reduce the cellular uptake of taxane molecules, further protecting the delicate axons that transmit sensation. The result is a physical barrier of sorts—cold-induced starvation of the drug at precisely the sites where neuropathy strikes first.

To test whether this mechanism translates into real clinical benefit, the research team searched six major databases—Scopus, PubMed/MEDLINE, ProQuest, ScienceDirect, SAGE Journals, and the Cochrane Library—from inception to July 17, 2025, without imposing date limits or restricting inclusion to randomized designs. The protocol was prospectively registered in PROSPERO before the final search update, a practice that helps guard against selective reporting. The team ultimately included fourteen studies: twelve randomized controlled trials and two retrospective cohort studies, all involving breast cancer patients receiving paclitaxel or nab-paclitaxel with cryotherapy as the primary preventive intervention.

The headline findings come from the comparative double-arm analyses, which directly compared cryotherapy against no cooling or alternative care. Patients who used cryotherapy had roughly 55 percent lower odds of developing moderate to severe neuropathy, measured as CTCAE Grade 2 or higher, with a relative risk of 0.45 and a 95 percent confidence interval of 0.27 to 0.77, a statistically significant result. Sensory neuropathy—the numbness and tingling that most often impair daily function—was reduced even more dramatically, with a relative risk of 0.35. On a second validated instrument, the Patient Neurotoxicity Questionnaire, the risk of reaching grade D or higher total scores fell to just 0.24 of the comparator risk, again statistically significant. Motor neuropathy, by contrast, showed no significant reduction, a finding the authors note honestly rather than glossing over.

Statistical heterogeneity across the comparative trials was low to moderate, which lends credibility to the pooled estimates. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS-I for the non-randomized cohorts, while the certainty of the evidence was graded with the GRADE framework. This methodological rigor matters, because meta-analyses of supportive-care interventions are frequently criticized for combining heterogeneous protocols and outcome measures. Here, the authors took the additional step of separating comparative outcomes from single-arm proportions, treating the latter as very low-certainty, purely descriptive evidence rather than folding them into the efficacy estimates.

That separation proved important. The single-arm studies, which reported neuropathy incidence in cryotherapy users without a control group, yielded a pooled CTCAE Grade 2 or higher proportion of 0.20, but with high heterogeneity and no comparator, this figure cannot demonstrate efficacy. Similarly, pooled tolerability outcomes—any adverse event at 19 percent, cold intolerance at 16 percent, and discontinuation of cryotherapy due to side effects at just 2 percent—are non-comparative and highly heterogeneous. The authors explicitly caution that these descriptive estimates should not be interpreted as proof of safety or effectiveness, a level of statistical humility that is refreshingly rare in the field.

Two clinically crucial outcomes remain unresolved. Chemotherapy dose reduction, which matters because neuropathy often forces oncologists to cut treatment short, showed a relative risk of 0.43 in favor of cryotherapy, but this estimate rested on only two studies with a confidence interval crossing unity and a p-value of 0.109. Treatment discontinuation due to neuropathy showed an even larger apparent benefit, with a relative risk of 0.22, yet the p-value of 0.163 and wide confidence intervals mean the result is underpowered and inconclusive. These are precisely the outcomes that would matter most to patients and oncologists alike, and the authors are candid that larger trials are needed before any firm claims can be made.

The practical appeal of cryotherapy is hard to overstate. Unlike pharmacological candidates such as duloxetine, which carries its own side-effect profile, cooling devices are inexpensive, non-invasive, and require no systemic exposure. The low discontinuation rate of 2 percent suggests that most patients can tolerate the discomfort of wearing frozen gloves and socks for the duration of an infusion, even if cold intolerance affects roughly one in six. For a therapy that could spare a substantial fraction of breast cancer patients from chronic numbness and pain, the risk-benefit calculus appears favorable on its face.

Still, the authors urge cautious clinical interpretation. The evidence base, while promising, is built on trials with variable cooling protocols, differing outcome instruments, and limited power for the outcomes that matter most. Standardized intervention parameters—exact temperatures, duration of cooling, and timing relative to drug infusion—have yet to be established, and until large, well-designed randomized trials confirm the effects on dose intensity and treatment completion, cryotherapy should be viewed as a promising but not yet definitive preventive strategy. What the current analysis does establish is that the biological rationale is sound, the comparative signal is consistent, and the barrier to testing at scale is remarkably low. In a field where patients have long been told to simply endure the tingling, the prospect that a pair of frozen gloves might protect the nerves that matter most is a finding worth taking seriously.

Subject of Research: Cryotherapy for preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with paclitaxel

Article Title: Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis

Article References: Prajoko, Y. W., Tjandra, K. C., Respati, D. R. P., Ar, A., Bulandari, B. L. A., Aryasatya, D. P., Rahmani, K., & Bima, R. C. S. (2026). Cryotherapy for preventing chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16971-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16971-7

Keywords: cryotherapy, chemotherapy-induced peripheral neuropathy, breast cancer, paclitaxel, nab-paclitaxel, meta-analysis, systematic review, sensory neuropathy, supportive oncology, taxane chemotherapy, CTCAE, nerve protection